What is AltPep?
AltPep Corporation is at the forefront of developing novel therapeutic and diagnostic solutions for amyloid diseases, including Alzheimer's and Parkinson's. The company's proprietary platform leverages custom-designed synthetic peptides engineered to target and neutralize the toxic oligomers implicated in these debilitating conditions. By focusing on early detection and intervention, AltPep aims to fundamentally alter the trajectory of diseases that impact a substantial portion of the global population, striving to transform the diagnostic and treatment landscape.
How much funding has AltPep raised?
AltPep has raised a total of $120.5M across 3 funding rounds:
Series A
$23.1M
Other Financing Round
$44.4M
Series B
$52.9M
Series A (2021): $23.2M with participation from Alexandria Venture Investments and Matrix Capital Management Company
Other Financing Round (2022): $44.4M, investors not publicly disclosed
Series B (2023): $52.9M supported by Section 32, Eli Lilly and Company Pvt, and Senator Investment Group
Key Investors in AltPep
Section 32
Section 32 is a venture capital firm focused on investing in cutting-edge technology, particularly in the healthcare and life sciences sectors. Backed by experienced professionals, the firm supports visionary entrepreneurs and innovative startups aiming for significant technological advancements.
Eli Lilly and Company Pvt
Eli Lilly and Company Pvt is the Indian subsidiary of the global biopharmaceutical giant, specializing in advanced treatments for chronic diseases. The company is committed to medical innovation and developing therapeutic options for conditions like diabetes and cancer.
Senator Investment Group
Senator Investment Group is an investment firm that focuses on asset allocation across global public equity and fixed income markets. The firm was founded in 2008 and is based in New York City.
What's next for AltPep?
With the recent influx of major strategic investment, AltPep is poised to accelerate the development of its pipeline of therapeutics and diagnostics. This substantial backing, categorized as a major enterprise-level funding, signals a critical growth phase for the company. The strategic capital is expected to fuel further research and development, clinical trials, and the expansion of its operational capabilities, positioning AltPep to make significant advancements in the fight against amyloid diseases.
See full AltPep company page
